Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
Scientists discovered a previously missed DNA mutation pattern in colorectal cancer, found in 3 independent datasets of 2616 tumors, suggesting a new mechanism of DNA damage accumulation. The pattern appears relatively late in tumor development and is associated with small insertions and deletions in DNA.
Researchers at UC Irvine propose a new framework to target mitochondrial dysfunction, a key contributor to immune effector cell-associated neurotoxicity syndrome, to make CAR T-cell therapy safer. The approach aims to repurpose existing drugs with established safety profiles, potentially accelerating the development of safer treatment ...
Researchers at Pusan National University investigated how chronic environmental stress drives immune dysfunction in cold tumors, revealing a key driver of NK-cell maladaptation: the GDF15-AhR axis. This axis sustains activation of stress-sensing receptors, gradually exhausting NK cells and enabling immune escape.
Researchers discovered that exhausted T cells can lose the exhaustion marker LAG3 to escape tumors and confer long-lasting immunity to cancer in mice. These cells play a critical role in generating a strong, durable memory response, which is essential for effective cancer immunotherapy.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
βIII-tubulin is frequently overexpressed in various cancers and associated with aggressive tumor characteristics and poor therapeutic responses. Targeting βIII-tubulin-associated regulatory networks may provide new strategies to overcome treatment resistance.
Researchers identify IL-26 as a key regulator that reprograms tumor cells to evade immune attack, promoting immune escape and resistance to anti-PD-1 therapy. Targeting IL-26 may improve immunotherapy outcomes and lead to new treatments for cancer and chronic inflammatory diseases.
A decade-long review of Kids First DRC shows how shared data expands research opportunities across diseases, institutions, and scientific disciplines. The resource has supported findings with potential to improve diagnosis, risk assessment, and treatment in pediatric care.
A new study published in JAMA Internal Medicine found that pilots and flight attendants have statistically significantly higher rates of death from breast, central nervous system, and prostate cancers and melanoma. The study used a large dataset and accounted for various factors to determine the occupation's impact on mortality.
Purine metabolism aberrantly reprogrammed in cancer to drive hyperproliferation and metastasis; key enzymes act as active drivers of tumorigenesis. Selective targeting of purine metabolism networks presents promising next-generation anticancer strategy.
The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.
Researchers discover a subset of clear cell ovarian cancers responsive to immunotherapy, driven by inflammation-related protein IL-17. IL-17 acts directly on cancer cells, creating an immune-permissive tumor microenvironment, enabling prediction of treatment response and contributing to personalized medicine.
A cohort study of 13,585 insured patients found racial disparities in endometrial cancer survival, with greater imbalances in risk of adverse tumor types and distant disease. Younger black patients had a 43% larger disparity compared to their white counterparts.
A new intraoperative imaging platform called ULTRA combines rapid tissue clearing, stimulated Raman scattering microscopy, and AI-based virtual staining to perform deep 3D histological imaging. This enables the visualization of key histological features across different glioma subtypes and facilitates glioma margin analysis.
MIT researchers found that inhibiting caspase-1, an enzyme involved in lung inflammation, reduces the risk of developing tumors. The drug has already gone into clinical trials for other diseases and may be tested as a preventative measure for people at high risk for lung cancer.
The PolyU developed AI Virtual Patient Simulation System combines multimodal data from genomic, medical imaging and clinical records to create a digital twin model tracking real-time changes in a patient's condition. It predicts the effectiveness of different cancer treatment options and supports personalized medical solutions.
Researchers developed a new approach called SHIFTERS that uses focused ultrasound to temporarily 'light up' solid tumors, giving cancer-fighting immune cells a target they can recognize. The technology allows doctors to control where and when treatment switches on, potentially making solid tumors easier to treat.
The updated guideline provides evidence-based recommendations on radiation therapy for adult patients with pancreatic cancer, clarifying its role in various settings. It recommends radiation therapy for patients with resectable, locally advanced, and metastatic disease, as well as those with recurrent or palliative needs.
Researchers developed a flexible microsystem to deliver light directly to internal cancer treatment sites, overcoming the limitation of traditional PDT. The system, powered wirelessly and containing tiny light-emitting components, shows promising results in laboratory tests, paving the way for more precise and effective cancer treatments.
Researchers developed a new therapeutic that targets cancer cells without harming healthy ones, significantly shrinking tumors in mice. The treatment, Pro-LYTAC, is activated within tumor cells and directed to lysosomes for degradation, restoring immune recognition of cancer cells.
A national study found that about half of prostate cancer patients receiving focal therapy fell outside the recommended patient groups, highlighting the need for evidence-based treatment decisions. The study emphasizes the importance of understanding which patients are most likely to benefit from promising new treatments.
Waiting times for cancer surgery have increased in the US, particularly at high-volume academic centers and among patients referred for definitive care. The study identifies factors that contribute to these delays, emphasizing the need for urgent system-level interventions to improve timely access to surgical care for cancer patients.
A research team at Case Western Reserve University is developing a non-invasive oral cancer test that can diagnose the disease in minutes. The test uses a simple oral swab and measures the ratio of two naturally occurring peptides, offering a promising alternative to current biopsy methods.
The study identified RTN4IP1 as a factor associated with poor prognosis in triple-negative breast cancer, promoting metastasis through NAD⁺ depletion and disrupting glycolysis and oxidative phosphorylation. RTN4IP1 interacts with AK4 to cause this metabolic disruption.
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
Scientists at Cancer Research UK Scotland Institute and University of Glasgow identify a new pathway for delivering antisense oligonucleotides (ASOs) into cells, enhancing the effectiveness of ASO-based therapy for pancreatic cancer and other diseases. The researchers found that ASOs enter cells via endocytosis and bind to specific rec...
Researchers identified two immune cell populations present in both initial and recurrent arthritis flares, suggesting an immune-memory disease. These cells may serve as biomarkers for high-risk patients or to guide targeted therapies to reduce side effects.
Researchers found molecular signs of changes in the blood of people exposed to air pollution, detectable years before diagnosis with lung cancer. The study suggests potential biomarkers for early detection and prevention strategies.
NGR Oncology has appointed multiple new leadership members to various subcommittees, including Rebecca Arend as Gynecology Oncologist Vice Chair of the Translational Science Committee and Robin Lockhorst as Chair of the Pharmacy Subcommittee. David Miyamoto was also appointed Radiation Oncology Vice Chair of the Translational Science C...
Researchers at the University of Colorado Anschutz Cancer Center have identified a previously unknown metabolic weakness in high-risk myelodysplastic syndromes (MDS), a discovery that could lead to more targeted treatments for this aggressive blood cancer. The study found that high-risk MDS stem cells are unusually dependent on nicotin...
Researchers developed a simple, fast, and low-cost blood test that identifies the tumor's biological fingerprint with over 90% accuracy. The test distinguishes between lung cancer patients and healthy individuals without DNA sequencing.
Researchers analyzed patient data from five clinical trials to evaluate the impact of adding hormone therapy on postoperative radiation outcomes. While traditional pathological features can identify patients at higher risk of recurrence, they do not predict treatment benefit.
Researchers identified NDRG1 as a key regulator of DNA damage repair, which can be targeted by the antimalarial drug quinacrine to trigger synthetic lethality in specific cancer subtypes. The study also reveals potential strategies for targeting DNA damage response based on NDRG1 expression.
A new study found that women living in socially vulnerable communities face a higher risk of death after an ovarian cancer diagnosis compared to those living in less vulnerable communities. The study also discovered that Black women face a significantly higher risk of death than white women, highlighting the importance of addressing ne...
Researchers explore bacterial extracellular vesicles as a tool for cancer diagnosis and treatment, with potential for targeted delivery of therapeutic molecules and immunotherapy. However, consistency and safety remain major challenges in this emerging field.
The partnership aims to increase enrollment in clinical trials, making research opportunities more accessible to patients. UCCCC and Lilly will work together to open studies faster and connect more patients with research opportunities.
Researchers developed a mathematical model that suggests adjusting treatment schedules over time may be more effective in managing tumors than rigid treatment plans. The study found that continuous therapy, rather than on-and-off treatment, can control the tumor and reduce toxicity, improving patient outcomes.
Recent research found that D-serine accelerates gastric cancer growth by suppressing cytotoxic T-cell activity and promoting immunosuppressive macrophages. High serum D-serine concentrations were linked to ICI therapy resistance in patients, suggesting its potential as a biomarker for disease progression.
Researchers identify seven-gene signature in eccDNA that predicts LUAD recurrence risk. eccDNA features provide new prognostic insights into lung adenocarcinoma.
Dr. Amoako's evidence-driven services improve early diagnosis, expand access to treatment, and advance locally led research in Ghana. Her work aims to strengthen childhood cancer care across the country.
Cancer cells' ability to evade the immune system is linked to changes in their surrounding environment, including nearby nutrients and conditions. Researchers discovered that altering these factors can thin the cancer cell's protective sugar coating, allowing the immune system to recognize and eliminate them.
A Japan-wide study found that growth hormone therapy improves adult height in childhood stem cell transplant survivors with short stature. However, treatment responses were highly variable and influenced by transplant-related factors such as total body irradiation and chronic graft-versus-host disease.
A large study reveals that dexrazoxane significantly reduces heart damage caused by chemotherapy in pediatric cancer patients years after treatment. The findings could change how doctors follow survivors for decades and provide families with reassurance about long-term effects.
Dr. Natalie Lui and her team are developing a molecular imaging agent, pan800, to identify lung cancer tumors during surgery. This technique aims to reduce complications and recurrence by enabling surgeons to achieve complete removal of tumors.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center are developing drug-based strategies to enhance cancer immunotherapy for melanoma and potentially other cancers. They identified two promising compounds that could strengthen T cell interaction with cancer cells or make tumor cells more susceptible to destruction by T cells.
Researchers have developed an experimental drug that tricks cancer cells into consuming more sugar than usual, then blocks their backup fuel source – fat. This approach puts cancer cells under so much stress that many die, demonstrating effectiveness in treating aggressive melanoma in mice.
A collaborative team led by Dana-Farber Cancer Institute has developed 665 next-generation patient-derived cancer models across 27 common and rare forms of cancer. The models are available as a resource to researchers worldwide, accelerating cancer advances with reliable and faithful replicas of original samples.
A new open resource of cancer models has enabled researchers to create the first large-scale map of the genes that cancers rely on to survive. The biobank, developed by the Wellcome Sanger Institute and collaborators, reveals potential weak points that could be targeted with future treatments.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
Researchers discovered that immunosuppressed patients with non-melanoma skin cancer have macrophages that fail to communicate effectively, leading to tumor progression. The study's findings suggest that boosting the functionality of these immune cells may lead to new treatment opportunities for these patients.
Researchers created nearly 700 new cancer models derived from patient tumors to aid in drug development. The models, representing 25 types of cancer, are now available for global use, providing a resource for identifying new drug targets and testing potential treatments.
A recent study published in Cancer Research found that sildenafil, the active ingredient in Viagra, can restrict cancer metastasis by limiting cancer cells' access to cholesterol. Combining sildenafil with statins may enhance this effect, potentially improving survival rates among cancer patients.
A team of researchers at UMass Amherst has developed an AI model, DiffuDose, that generates a patient's radiation dose map with gold-standard accuracy in under 23 seconds. This technology has the potential to unlock the full potential of radiopharmaceutical therapy for prostate cancer treatment.
UC San Diego Health has been ranked as the top care facility in California and among the top 20 in the nation for eight medical specialties. The institution achieved this distinction through its patient-dedicated, collaborative spirit and commitment to delivering outstanding care.
A cohort study revealed racial differences in sonographic evaluation, with a 76% completion rate and excellent cancer exclusion ability in Black women despite fibroids impairing endometrial visibility. Fibroid presence did not hinder cancer detection accuracy.
The Sylvester Comprehensive Cancer Center has been ranked the No. 1 cancer program in Florida and No. 23 nationally by US News & World Report. The center's multidisciplinary teams provide access to new therapies and innovative clinical trials, making it a destination for patients seeking advanced care.
Researchers have identified a promising strategy to improve the effectiveness of targeted therapies in advanced prostate cancer. By combining ADCs with a drug that blocks BCL-XL, they triggered greater cancer cell death and slowed tumor growth. The approach could offer a new strategy for improving antibody-drug conjugates against metas...
A new study found that S100–RAGE signaling is a key driver of early drug resistance in tumors, making it a promising target for treatment. Analyzing 47 patients and 109 pretreatment metastatic lesions treated with trastuzumab deruxtecan, researchers identified this pathway as a crucial factor in tumor resistance.
Researchers discovered a protein called TRAILshort that suppresses T-cell activity and reduces the effectiveness of CAR-T cell therapy in cancer patients. Elevated levels of TRAILshort were found in various cancers, infectious diseases, and autoimmune disorders.
A new study found that cells of the same chronological age can follow dramatically different biological aging paths. Tissues become a mosaic of biologically younger and older cells, with some individual cells aging much faster than others.